Barclays
IMGN

Barclays’s Immunogen Inc IMGN Stock Holding History

Barclays’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-642,156
Closed -$19M – 5474
2023
Q4 		$19M Buy
642,156
+299,429
+87% +$5.96M 0.01% 1081
2023
Q3 		$5.44M Buy
342,727
+76,185
+29% +$1.27M ﹤0.01% 1282
2023
Q2 		$5.03M Sell
266,542
-584,193
-69% -$6.9M ﹤0.01% 1341
2023
Q1 		$3.27M Buy
850,735
+70,086
+9% +$299K ﹤0.01% 1832
2022
Q4 		$3.87M Buy
780,649
+168,152
+27% +$912K ﹤0.01% 1802
2022
Q3 		$2.93M Buy
612,497
+595,402
+3,483% +$3.14M ﹤0.01% 1494
2022
Q2 		$76K Sell
17,095
-26,918
-61% -$117K ﹤0.01% 3885
2022
Q1 		$209K Sell
44,013
-454,311
-91% -$2.52M ﹤0.01% 3407
2021
Q4 		$3.7M Buy
498,324
+292,628
+142% +$1.82M ﹤0.01% 1933
2021
Q3 		$1.17M Buy
205,696
+32,163
+19% +$186K ﹤0.01% 2693
2021
Q2 		$1.14M Sell
173,533
-256,121
-60% -$1.79M ﹤0.01% 2569
2021
Q1 		$3.48M Buy
429,654
+238,835
+125% +$1.95M ﹤0.01% 1825
2020
Q4 		$1.23M Sell
190,819
-16,394
-8% -$95.6K ﹤0.01% 2608
2020
Q3 		$746K Sell
207,213
-102,747
-33% -$415K ﹤0.01% 2933
2020
Q2 		$1.43M Buy
309,960
+173,705
+127% +$739K ﹤0.01% 2433
2020
Q1 		$464K Sell
136,255
-151,729
-53% -$663K ﹤0.01% 3655
2019
Q4 		$1.47M Buy
287,984
+35,138
+14% +$119K ﹤0.01% 3305
2019
Q3 		$612K Sell
252,846
-86,046
-25% -$228K ﹤0.01% 4088
2019
Q2 		$735K Buy
338,892
+224,912
+197% +$532K ﹤0.01% 3991
2019
Q1 		$309K Buy
113,980
+51,460
+82% +$223K ﹤0.01% 4511
2018
Q4 		$300K Sell
62,520
-13,653
-18% -$82.8K ﹤0.01% 4285
2018
Q3 		$722K Buy
76,173
+56,640
+290% +$544K ﹤0.01% 3954
2018
Q2 		$190K Sell
19,533
-89,822
-82% -$947K ﹤0.01% 4770
2018
Q1 		$1.15M Buy
109,355
+38,349
+54% +$379K ﹤0.01% 3036
2017
Q4 		$455K Sell
71,006
-31,299
-31% -$193K ﹤0.01% 3944
2017
Q3 		$784K Buy
102,305
+50,544
+98% +$336K ﹤0.01% 3216
2017
Q2 		$368K Sell
51,761
-4,616
-8% -$21.1K ﹤0.01% 3824
2017
Q1 		$218K Buy
56,377
+38,789
+221% +$113K ﹤0.01% 4225
2016
Q4 		$35K Buy
17,588
+15,656
+810% +$31.4K ﹤0.01% 5363
2016
Q3 		$5K Sell
1,932
-100,967
-98% -$294K ﹤0.01% 6033
2016
Q2 		$317K Buy
102,899
+97,313
+1,742% +$610K ﹤0.01% 3586
2016
Q1 		$45K Buy
5,586
+4,211
+306% +$35.6K ﹤0.01% 4840
2015
Q4 		$17K Sell
1,375
-23,478
-94% -$289K ﹤0.01% 5250
2015
Q3 		$223K Buy
24,853
+20,654
+492% +$302K ﹤0.01% 4068
2015
Q2 		$59K Sell
4,199
-290,311
-99% -$3.19M ﹤0.01% 5046
2015
Q1 		$2.35M Buy
294,510
+128,294
+77% +$929K ﹤0.01% 2158
2014
Q4 		$997K Buy
166,216
+21,067
+15% +$193K ﹤0.01% 3214
2014
Q3 		$1.45M Buy
145,149
+44,995
+45% +$509K ﹤0.01% 2969
2014
Q2 		$1.1M Sell
100,154
-9,883
-9% -$124K ﹤0.01% 3239
2014
Q1 		$1.54M Sell
110,037
-12,026
-10% -$190K ﹤0.01% 2811
2013
Q4 		$1.71M Sell
122,063
-29,929
-20% -$460K ﹤0.01% 2838
2013
Q3 		$2.58M Buy
151,992
+8,371
+6% +$147K ﹤0.01% 2300
2013
Q2 		$2.38M Buy
+143,621
New +$2.33M ﹤0.01% 2353

Other funds holding IMGN

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Barclays's IMGN Position: Q1 2024 in Review

Barclays sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 642,156 shares — an estimated $19M sold.

Barclays first reported a position in IMGN in Q2 2013 and held it in 43 quarters. The position peaked at $19M in Q4 2023. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.

  • Barclays reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
  • Barclays sold 642,156 Immunogen Inc shares in Q1 2024, an estimated $19M.
  • Barclays first reported a position in Immunogen Inc in Q2 2013 and held it in 43 quarters.
  • Barclays's Immunogen Inc position peaked at $19M in Q4 2023.
  • 3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.

Based on Barclays's 13F filing for Q1 2024, filed 15 May 2024.